अApnaFunda
Menu

JB CHEMICALS & PHARMACEUTICA (JBCHEPHARM)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIESTORRENT PHARMACEUTICALS

Share price

Closing priceAdjusted for splits and bonus issues.

₹1,754.6 latest close · +8.0% over the last 90 sessions

₹1,500₹1,600₹1,700₹1,800Apr 16May 14Jun 9Jul 2Jul 28Aug 22 ₹1,500₹1,600₹1,700₹1,800Apr 16Jun 20Aug 22

₹1,754.6 month-end · −10.5% over 12 months

₹1,600₹1,800Aug '24Oct '24Jan '25Mar '25Jun '25Aug '25 ₹1,600₹1,800Aug '24Feb '25Aug '25

₹1,754.6 month-end · +99.1% over 3 years

₹1,000₹1,500₹2,000Aug '22Mar '23Oct '23Jun '24Jan '25Aug '25 ₹1,000₹1,500₹2,000Aug '22Feb '24Aug '25

₹1,754.6 month-end · +1010.5% since Jan '19

₹0₹1,000₹2,000Jan '19May '20Sep '21Dec '22Apr '24Aug '25 ₹0₹1,000₹2,000Jan '19May '22Aug '25

52-week range ₹1385.75 to ₹1991.95 · 1-year volatility 31.0%

How rough has the ride been?

Maximum drawdown-26.5%recovered 2022-09
1-year volatility31.0%annualised

Drawdown from peak

0%−10%−20%202020212022202320242025−26.4% 0%−10%−20%202020222024−26.4%
Largest drawdowns

-26.5% (2021-09 peak to 2022-06 low, recovered 2022-09)

-23.6% (2024-08 peak to 2025-05 low, not yet recovered)

-23.0% (2020-02 peak to 2020-03 low, recovered 2020-05)

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE82nd▲ 3 pts vs a year ago
  • Op. margin75thflat vs a year ago
  • Revenue growth63rd▲ 15 pts vs a year ago
  • EPS growth63rdflat vs a year ago
  • Debt/equity ↓92nd▲ 36 pts vs a year ago
  • Cash cycle ↓61st▲ 4 pts vs a year ago
  • P/E ↓35th▲ 5 pts vs a year ago
  • 12M momentum55th▲ 9 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

Key figures

52-week range

₹1385.75₹1991.95
61% of the way from its 52-week low to its high

Price risk

1Y volatility
31.0%
Beta vs sector
1-year daily
0.59

Are profits backed by cash?

2 of 3checks within range1 near a threshold
Other income reliance—Not enough data

Not enough reported data to compute this.

Tax rate—Not enough data

Not enough reported data to compute this.

Cash conversion1.25xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 1.25x (cash from operations ₹2,407 cr, net profit ₹1,922 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow3 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 3. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history—Not enough data

Not enough reported data to compute this.

Capital work in progress4% of fixed assetsWithin range

Capital work-in-progress is 4% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days—Not enough data

Not enough reported data to compute this.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 2 years, FIIs added 8.8 pts; promoters trimmed 6.1 pts.
  • The number of shareholders rose from 55,965 to 63,948 (+14%) between Jun 2023 and Mar 2025.

Holdings, Mar '25

How each group changed

GroupJun '23Mar '25Change
Promoters53.9%47.8%-6.1 pts
FIIs9.5%18.3%+8.8 pts
DIIs18.6%18.7%+0.1 pts
Public and others17.9%15.1%-2.8 pts

Number of shareholders

63,948shareholders+14% since Jun '23
56k60k63k67k Jun '23Dec '23Jun '24Dec '24Mar '25
Jun '23: 55,965
Sep '23: 60,817
Dec '23: 63,230
Mar '24: 63,892
Jun '24: 66,953
Sep '24: 62,743
Dec '24: 62,081
Mar '25: 63,948
 56k60k63k67k Jun '23Mar '24Dec '24Mar '25
Jun '23: 55,965
Sep '23: 60,817
Dec '23: 63,230
Mar '24: 63,892
Jun '24: 66,953
Sep '24: 62,743
Dec '24: 62,081
Mar '25: 63,948

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What changed?

23 events since Jun '19

  1. JunPromoterPromoter holding fell 5.8 pts to 47.8% (largest drop in the history since 2019-01).
  2. JunInstitutionsFII + DII holding rose 6.6 pts over 2 quarters to 37.0%.
  3. JunPeer rankMoved into the 2nd quartile of Health Technology on EPS growth (from the 3rd quartile).
  4. MarPeer rankSlipped to the 3rd quartile of Health Technology on EPS growth (from the 2nd quartile).
  5. JunPeer rankSlipped to the 2nd quartile of Health Technology on EPS growth (from the top quartile).
  6. JunSharesShare count is up 6.7% over 12 months.
  7. AprValuationP/E crossed above the 90th percentile of its own history to date (57.5x).
  8. MarResultsRevenue (TTM) reached a new high of ₹3,385 cr.
Show 15 earlier events
  1. MarPeer rankMoved into the top quartile of Health Technology on EPS growth (from the 2nd quartile).
  2. JunResultsYear-on-year EPS growth turned positive.
  3. JunPeer rankMoved into the top quartile of Health Technology on ROCE (from the 2nd quartile).
  4. SepPriceRegained the 2021-09 peak, 3 months after the low.
  5. JulValuationP/E crossed above the 90th percentile of its own history to date (35.4x).
  6. JunResultsYear-on-year EPS growth turned negative.
  7. JunPriceFell 26% from the Sep 2021 peak to the Jun 2022 low.
  8. JunPeer rankSlipped to the 2nd quartile of Health Technology on ROCE (from the top quartile).
  9. SepValuationP/E crossed above the 90th percentile of its own history to date (32.3x).
  10. JunResultsRevenue (TTM) reached a new high of ₹2,043 cr.
  11. JunPeer rankSlipped to the 2nd quartile of Health Technology on EPS growth (from the top quartile).
  12. FebValuationP/E crossed above the 90th percentile of its own history to date (31.9x).
  13. JunResultsRevenue (TTM) reached a new high of ₹1,775 cr.
  14. JunPeer rankMoved into the top quartile of Health Technology on ROCE (from the 2nd quartile).
  15. JunPeer rankMoved into the 2nd quartile of Health Technology on ROCE (from the 3rd quartile).

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history95 months · 2019-01 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-11—————
2026-10—————
2026-09—————
2026-08—————
2026-07—————
2026-06—————
2026-05—————
2026-04—————
2026-03—————
2026-02—————
2026-01—————
2025-12—————
2025-11—————
2025-10—————
2025-09—————
2025-0841.3x₹3917 cr19.2%26.0%0.0x
2025-0741.9x₹3917 cr19.2%26.0%0.0x
2025-0639.5x₹3917 cr19.2%26.0%0.0x
2025-0540.9x₹3830 cr21.9%25.0%0.1x
2025-0439.1x₹3830 cr21.9%25.0%0.1x
2025-0339.2x₹3830 cr21.9%25.0%0.1x
2025-0242.0x₹3712 cr20.9%25.0%0.1x
2025-0144.7x₹3712 cr20.9%25.0%0.1x
2024-1246.6x₹3712 cr20.9%25.0%0.1x
2024-1145.8x₹3593 cr20.1%25.0%0.1x
2024-1051.4x₹3593 cr20.1%25.0%0.1x
2024-0949.5x₹3593 cr20.1%25.0%0.1x
2024-0855.0x₹3485 cr18.9%25.0%0.1x
2024-0754.1x₹3485 cr18.9%25.0%0.1x
2024-0649.2x₹3485 cr18.9%25.0%0.1x
2024-0554.7x₹3385 cr20.8%22.0%0.2x
2024-0457.5x₹3385 cr20.8%22.0%0.2x
2024-0349.7x₹3385 cr20.8%22.0%0.2x
2024-0258.3x₹3149 cr16.5%22.0%0.2x
2024-0163.3x₹3149 cr16.5%22.0%0.2x
2023-1261.2x₹3149 cr16.5%22.0%0.2x
2023-1155.6x₹3149 cr16.5%22.0%0.2x
2023-1052.8x₹3149 cr16.5%22.0%0.2x
2023-0955.9x₹3149 cr16.5%22.0%0.2x
2023-0852.5x₹3149 cr16.5%22.0%0.2x
2023-0747.4x₹3149 cr16.5%22.0%0.2x
2023-0644.8x₹3149 cr16.5%22.0%0.2x
2023-0542.2x₹2424 cr18.1%23.0%0.0x
2023-0442.4x₹2424 cr18.1%23.0%0.0x
2023-0339.3x₹2424 cr18.1%23.0%0.0x
2023-0239.1x₹2424 cr18.1%23.0%0.0x
2023-0141.0x₹2424 cr18.1%23.0%0.0x
2022-1238.7x₹2424 cr18.1%23.0%0.0x
2022-1140.4x₹2424 cr18.1%23.0%0.0x
2022-1039.6x₹2424 cr18.1%23.0%0.0x
2022-0938.3x₹2424 cr18.1%23.0%0.0x
2022-0835.4x₹2424 cr18.1%23.0%0.0x
2022-0735.4x₹2424 cr18.1%23.0%0.0x
2022-0631.6x₹2424 cr18.1%23.0%0.0x
2022-0528.1x₹2043 cr24.8%33.0%0.0x
2022-0429.3x₹2043 cr24.8%33.0%0.0x
2022-0327.2x₹2043 cr24.8%33.0%0.0x
2022-0227.8x₹2043 cr24.8%33.0%0.0x
2022-0130.0x₹2043 cr24.8%33.0%0.0x
2021-1230.6x₹2043 cr24.8%33.0%0.0x
2021-1128.0x₹2043 cr24.8%33.0%0.0x
2021-1028.8x₹2043 cr24.8%33.0%0.0x
2021-0932.3x₹2043 cr24.8%33.0%0.0x
2021-0829.5x₹2043 cr24.8%33.0%0.0x
2021-0731.4x₹2043 cr24.8%33.0%0.0x
2021-0628.7x₹2043 cr24.8%33.0%0.0x
2021-0541.1x₹1775 cr19.0%23.0%0.0x
2021-0439.6x₹1775 cr19.0%23.0%0.0x
2021-0335.8x₹1775 cr19.0%23.0%0.0x
2021-0231.9x₹1775 cr19.0%23.0%0.0x
2021-0128.5x₹1775 cr19.0%23.0%0.0x
2020-1228.9x₹1775 cr19.0%23.0%0.0x
2020-1128.6x₹1775 cr19.0%23.0%0.0x
2020-1028.6x₹1775 cr19.0%23.0%0.0x
2020-0928.1x₹1775 cr19.0%23.0%0.0x
2020-0821.8x₹1775 cr19.0%23.0%0.0x
2020-0720.8x₹1775 cr19.0%23.0%0.0x
2020-0620.1x₹1775 cr19.0%23.0%0.0x
2020-0528.3x₹1643 cr13.1%18.0%0.0x
2020-0423.1x₹1643 cr13.1%18.0%0.0x
2020-0321.1x₹1643 cr13.1%18.0%0.0x
2020-0222.4x₹1643 cr13.1%18.0%0.0x
2020-0120.6x₹1643 cr13.1%18.0%0.0x
2019-1217.6x₹1643 cr13.1%18.0%0.0x
2019-1116.4x₹1643 cr13.1%18.0%0.0x
2019-1014.2x₹1643 cr13.1%18.0%0.0x
2019-0915.3x₹1643 cr13.1%18.0%0.0x
2019-0815.8x₹1643 cr13.1%18.0%0.0x
2019-0715.5x₹1643 cr13.1%18.0%0.0x
2019-0615.5x₹1643 cr13.1%18.0%0.0x
2019-0522.6x₹1408 cr9.6%11.0%0.0x
2019-0420.8x₹1408 cr9.6%11.0%0.0x
2019-0321.7x₹1408 cr9.6%11.0%0.0x
2019-0219.7x₹1408 cr9.6%11.0%0.0x
2019-0119.1x₹1408 cr9.6%11.0%0.0x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback